Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire Says Vpriv Is A Viable Option for Cerezyme Patients; Gets PDUFA For Firazyr

This article was originally published in The Pink Sheet Daily

Executive Summary

Firazyr could enjoy a dosing advantage over other HAE drugs currently on the U.S. marketplace if it can get approval from FDA.
Advertisement

Related Content

Despite Rival's Supply Problems, No Guarantee That Shire Will Re-File Replagal In U.S.
Despite Rival's Supply Problems, No Guarantee That Shire Will Re-File Replagal In U.S.
Is Europe's HAE Market Big Enough To Sustain All The Competitors?
Shire Finally Able To Move Firazyr Forward
EU Approves Shire's Vpriv For Gaucher Disease, As Shortages Of Genzyme's Rival Product Ease
EU Approves Shire's Vpriv For Gaucher Disease, As Shortages Of Genzyme's Rival Product Ease
Jerini’s Icatibant Falters in U.S., Wins In Europe

Topics

Advertisement
UsernamePublicRestriction

Register

PS071990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel